Ribo Closed $40M Series E1 Financing to support global development of the diversified pipelines and continuous advancement of siRNA technologies.-News-Suzhou Ribo Life Science Co., Ltd

About Ribo

Science

Pipeline

Collaboration

Investors

Careers

About Ribo

International R&D Center

Scientific Advisory Board

Our Culture

News

About Oligonucleotide Therapeutics

Technological Innovations

Intellectual Property

Pipeline

Products

Clinical Trials

BD and Collaboration

Overview

Our Culture

Career Development

Recruitment

CN

News

International R&D Center

Scientific Advisory Board

Ribo Closed $40M Series E1 Financing to support global development of the diversified pipelines and continuous advancement of siRNA technologies.

Jul 29,2022

Last : Ribo Announces China CDE Approval of Clinical Trial Application of RBD7022 First-In-Human Clinical Trial in China for Treatment of Hyperlipidemia.

Next : Ribocure Pharmaceuticals Moves Into GoCo Clinic - Putting North Europe in the Spotlight Within Oligonucleotide Therapeutics

友情链接:百度一下搜索 360搜索网站首页尊龙凯时人生就是博